

Shire is the leading biotechnology company focused on serving people with rare diseases.

Shire is a global leader in hematology:



Longest heritage

70+ years of innovating in hemophilia.

Broad portfolio

A portfolio of 10 products across 9 hemophilia indications, demonstrating our commitment to the rare bleeding disorder community.


Standard of care

With more than 200 clinical studies over 50 years, factor treatment is recognized as the standard of care globally in treating hemophilia.^{1,2,3} Shire's factor VIII portfolio has established safety and efficacy.

Hemophilia is an **inherited bleeding disorder** that causes longer-than-normal bleeding due to absent or deficient clotting in the blood.⁴ Factor replacement therapy given on-demand or prophylactically is recognized as the standard of care globally for controlling or preventing bleeds.³



Some patients may develop **inhibitors to treatment**.⁶ It means their immune systems are producing antibodies that prevent factor treatments from working.



Approximately 20% of people with hemophilia A and 3% of people with hemophilia B develop inhibitors.⁷

Globally, there are more than **180,000 people** currently diagnosed with hemophilia A and hemophilia B.⁵



Shire: Innovating in hemophilia

Our innovation strategy evaluates new technologies, such as gene therapy, that can build upon the success of current standards and further improve patient outcomes. Shire is working to shape the course of the future with patient-focused innovation, raising global standards of care and advancing treatments to optimize outcomes for every patient.

Approximately

75%

of those with hemophilia around the world still **receive inadequate treatment or do not have access to treatment**.⁸

Our aim is an **individualized approach** as every patient is unique.

1. Data on file. Hemophilia Trials with Factor. 2016.
2. FDA Web site. User fee billable biologic products and potencies approved under Section 351 of the PHS Act. <http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm122936.htm>. Last accessed January 2018.
3. World Federation of Hemophilia. Guidelines for the Management of Hemophilia. Available at: <https://www1.wfh.org/publication/files/pdf-1472.pdf>. Last accessed January 2018.
4. World Federation of Hemophilia. "What is hemophilia?" World Federation of Hemophilia website. <http://www.wfh.org/en/page.aspx?pid=646>. Last accessed January 2018.
5. World Federation of Hemophilia. Report on the Annual Global Survey 2016. Available at: <https://www1.wfh.org/publication/files/pdf-1669.pdf>. Last accessed January 2018.
6. National Hemophilia Foundation. "Inhibitors & Other Complications." National Hemophilia Foundation website. <https://www.hemophilia.org/Bleeding-Disorders/Inhibitors-Other-Complications>. Last accessed January 2018.
7. CDC website. Inhibitors. Available at: <https://www.cdc.gov/ncbddd/hemophilia/inhibitors.html>. Last accessed January 2018.
8. National Hemophilia Foundation. Fast facts. 2017. Available at: <https://www.hemophilia.org/About-Us/Fast-Facts>. Last accessed January 2018.